These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22826453)

  • 1. Sitagliptin-associated angioedema.
    Gosmanov AR; Fontenot EC
    Diabetes Care; 2012 Aug; 35(8):e60. PubMed ID: 22826453
    [No Abstract]   [Full Text] [Related]  

  • 2. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
    Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
    Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates.
    Millot I; Plancade D; Hosotte M; Landy C; Nadaud J; Ragot C; Graffin B; Drouet C; Kanny G
    Br J Anaesth; 2012 Nov; 109(5):827-9. PubMed ID: 23066003
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?
    Lestner JM; Baburaj R; Edwards CM
    Br J Hosp Med (Lond); 2011 Jul; 72(7):412-3. PubMed ID: 21841617
    [No Abstract]   [Full Text] [Related]  

  • 5. Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin.
    Beaudouin E; Defendi F; Picaud J; Drouet C; Ponard D; Moneret-Vautrin DA
    Eur Ann Allergy Clin Immunol; 2014 May; 46(3):119-22. PubMed ID: 24853572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
    Tanaka K; Ogawa Y; Shimada S
    J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
    [No Abstract]   [Full Text] [Related]  

  • 7. DPP-IV inhibitor-associated arthralgias.
    Chaicha-Brom T; Yasmeen T
    Endocr Pract; 2013; 19(2):377. PubMed ID: 23598537
    [No Abstract]   [Full Text] [Related]  

  • 8. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.
    Goodwin SR; Reeds DN; Royal M; Struthers H; Laciny E; Yarasheski KE
    J Clin Endocrinol Metab; 2013 Feb; 98(2):743-51. PubMed ID: 23264399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated hepatic enzymes potentially associated with sitagliptin.
    Gross BN; Cross LB; Foard J; Wood Y
    Ann Pharmacother; 2010 Feb; 44(2):394-5. PubMed ID: 20103614
    [No Abstract]   [Full Text] [Related]  

  • 10. Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
    Mas-Vidal A; Santos-Juanes J; Esteve-Martinez A; Caminal-Montero L; Coto-Segura P
    Australas J Dermatol; 2012 Feb; 53(1):70-2. PubMed ID: 22309337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin intolerance.
    Kargili A; Karakurt F; Kankilic MN; Kankilic ES; Bozkurtl B
    Allergol Immunopathol (Madr); 2010; 38(5):290-1. PubMed ID: 20554368
    [No Abstract]   [Full Text] [Related]  

  • 12. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
    Yokota K; Igaki N
    Intern Med; 2012; 51(15):2041-4. PubMed ID: 22864134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of drug-induced hepatic injury associated with sitagliptin.
    Toyoda-Akui M; Yokomori H; Kaneko F; Shimizu Y; Takeuchi H; Tahara K; Motoori T; Ohbu M; Oda M; Hibi T
    Intern Med; 2011; 50(9):1015-20. PubMed ID: 21532224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angioedema following initiation of glecaprevir/pibrentasvir while on sitagliptin.
    Schneider A; Ramesh M
    J Allergy Clin Immunol Pract; 2019; 7(6):2068-2069. PubMed ID: 30779957
    [No Abstract]   [Full Text] [Related]  

  • 15. DPP-IV inhibitor may affect spermatogenesis.
    Hibi H; Ohori T; Yamada Y
    Diabetes Res Clin Pract; 2011 Aug; 93(2):e74-e75. PubMed ID: 21636156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
    Desai S; Brinker A; Swann J; Iyasu S
    Arch Intern Med; 2010 Jul; 170(13):1169-71. PubMed ID: 20625027
    [No Abstract]   [Full Text] [Related]  

  • 17. GLP-1-based therapies: the dilemma of uncertainty.
    Spranger J; Gundert-Remy U; Stammschulte T
    Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
    Stricklin SM; Stoecker WV; Rader RK; Hood AF; Litt JZ; Schuman TP
    Dermatol Online J; 2012 Feb; 18(2):9. PubMed ID: 22398230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.
    Kao DP; Kohrt HE; Kugler J
    Diabet Med; 2008 Oct; 25(10):1229-30. PubMed ID: 19046202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan.
    Sato D; Sato Y; Masuda S; Kimura H
    Int J Clin Pharm; 2012 Dec; 34(6):917-24. PubMed ID: 22941471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.